Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Brazil's 2008-09 dengue programme features more specific rapid diagnostics

This article was originally published in Clinica

Executive Summary

Faster dengue diagnostics, capable of more precisely defining the serotype of the infection, is a leading component of Brazil's dengue strategy in 2008-09. So said the health ministry at the end of October, following the launch of a new national programme. The overall federal budget for the programme has increased 23% on 2007, to R$1.08bn (US$492m). The key to patient management is knowing, as early as possible, which of four serotypes are involved; infection with more than one of these causes the potentially fatal form of dengue fever.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT042014

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel